Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Equity IncomeIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Beam Therapeutics (BEAM) Shares Outstanding (Weighted Average) (2019 - 2025)

Beam Therapeutics (BEAM) has disclosed Shares Outstanding (Weighted Average) for 7 consecutive years, with $98.9 million as the latest value for Q4 2025.

  • On a quarterly basis, Shares Outstanding (Weighted Average) rose 20.16% to $98.9 million in Q4 2025 year-over-year; TTM through Dec 2025 was $98.9 million, a 20.16% increase, with the full-year FY2025 number at $98.9 million, up 20.16% from a year prior.
  • Shares Outstanding (Weighted Average) was $98.9 million for Q4 2025 at Beam Therapeutics, up from $97.6 million in the prior quarter.
  • In the past five years, Shares Outstanding (Weighted Average) ranged from a high of $102.0 million in Q2 2025 to a low of $60.2 million in Q1 2021.
  • A 5-year average of $77.3 million and a median of $75.7 million in 2023 define the central range for Shares Outstanding (Weighted Average).
  • Peak YoY movement for Shares Outstanding (Weighted Average): soared 95.96% in 2021, then grew 3.94% in 2024.
  • Beam Therapeutics' Shares Outstanding (Weighted Average) stood at $64.2 million in 2021, then grew by 9.01% to $70.0 million in 2022, then increased by 10.19% to $77.2 million in 2023, then rose by 6.69% to $82.3 million in 2024, then rose by 20.16% to $98.9 million in 2025.
  • Per Business Quant, the three most recent readings for BEAM's Shares Outstanding (Weighted Average) are $98.9 million (Q4 2025), $97.6 million (Q3 2025), and $102.0 million (Q2 2025).